1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Palbociclib 100mg: new trials by email Literature Review of Palbociclib 100mg trials Research Report on Palbociclib 100mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Terminated | University of Kansas Medical Center | 3 | 2018-10-15 | 2024-03-05 |
| Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor - Breast Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 180 | 2016-04-08 | 2026-04-13 |
Breast Neoplasms (1)
Canadian Cancer Trials Group (1) · University of Kansas Medical Center (1)
Canada (1) · United States (1)
Anil A. Joy (1) · Lauren Nye, MD (1)